Table 1 General characteristics of the study population
General characteristics | Fibrate /Niacin (n = 22) | Fluvastatin (n = 10) | Pravastatin (n = 114) | Simvastatin ± Ezetimab (n = 612) | Atorvastatin (n = 181) | Rosuvastatin (n = 104) |
|---|---|---|---|---|---|---|
Mean age, Y (SD) | 57.5 ± 4.7 | 62.3 ± 5.5 | 58.1 ± 5.2 | 58.3 ± 5.2 | 59.0 ± 4.6 | 57.7 ± 5.5 |
Men, n (%) | 13 (59.1) | 4 (40) | 71 (62.3) | 352 (57.5) | 126 (69.6) | 72 (69.2) |
Mean BMI, kg/m2 (SD) | 31.0 ± 2.8 | 31.8 ± 4.9 | 31.3 ± 4.5 | 31.1 ± 4.4 | 31.4 ± 4.8 | 31.6 ± 4.7 |
Smoking history, n (%) | 18 (85.7) | 8 (80) | 86 (75.4) | 451 (73.8) | 141 (78.3) | 86 (82.7) |
HTN (Yes), n (%) | 10 (45.5) | 8 (80) | 53 (46.5) | 255 (41.7) | 88 (48.6) | 46 (44.7) |
Diabetes (Yes), n (%) | 7 (31.8) | 6 (60) | 39 (34.2) | 224 (37) | 66 (36.9) | 24 (23.5) |
CVD (yes), n (%) | 3 (13.6) | 5 (50) | 37 (32.7) | 119 (19.5) | 77 (43) | 39 (38.2) |